Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine maintenance versus observation in older AML/RAEB patients in remission after chemotherapy
NL-OMON20498Phase 3Recruiting
- Sponsor
- HOVON
- Start
- Jun 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in acute myeloid leukemia (AML) and myelodysplastic syndrome with excess blasts (MDS-EB) comparing Observation with Vidaza maintenance (2 arms). Primary endpoint: Disease-free survival. Started Jun 2009; status: recruiting.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome with excess blasts (MDS-EB)
Beyond the preview
Go deeper on NL-OMON20498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20498.